论文部分内容阅读
Russell于1971年首先报告,转移癌患者尿多胺排泄量增加,实体肿瘤和血液肿瘤患者尿多胺水平亦展示一定型式的增高,而且其增高程度与肿瘤活性相关,故认为尿多胺水平可作为估价肿瘤活性的一种诊断工具。嗣后许多研究者将多胺作为肿瘤的生化标志,探讨各种体液多胺测定的临床应用价值。Durie曾报告血液肿瘤和实体肿瘤患者尿液中腐胺,精脒和精胺的浓度均显著增高,其中精胺值范围在癌患者与正常志愿者之间并无重叠
Russell first reported in 1971 that urinary polyamine excretion was increased in patients with metastatic cancer. Urinary polyamine levels in patients with solid tumors and hematological malignancies also showed a certain pattern of increase, and the degree of increase was correlated with tumor activity, so that urinary polyamine levels may be considered As a diagnostic tool to evaluate tumor activity. Afterwards, many researchers used polyamines as biochemical markers of tumors to investigate the clinical application value of various body fluid polyamines. Durie has reported that the concentrations of putrescine, spermidine and spermine in urine of patients with hematological and solid tumors are significantly increased, and there is no overlap in the range of spermine between cancer patients and normal volunteers.